Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.54 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CD38 | P28907 | 1/20 | 0.45 |
| ▸ | ATF1 | P18846 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15176520 | 0.86 | KMT2A (0.59) | NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL16762857 | 0.85 | HTT (0.51) | NPC1RAB9ASMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL3369722 | 0.83 | RAB9A (0.68) | MAP3K5NPC1RAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL16762991 | 0.82 | METTL3 (0.48) | MCHR1MAP3K5 | |
| SCHEMBL16762855 | 0.79 | DGAT1 (0.54) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL15176541 | 0.79 | NPC1 (0.46) | MAP3K5NPC1RAB9ACYP2C9NR4A2 | |
| SCHEMBL16762864 | 0.79 | DGAT1 (0.56) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL16762947 | 0.79 | SMN1; SMN2 (0.50) | MAP3K5NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL15176683 | 0.77 | ALDH1A1 (0.53) | NPC1RAB9ACYP2C9NR4A2LMNA | |
| SCHEMBL16762742 | 0.76 | EGLN1 (0.43) | MAP3K5NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271969-B2 | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | KAINOS MEDICINE, INC. (KR) | 2016-03-01 | — | — | US | disclosed |
| US-20150157611-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE I ENZYME | KAINOS MEDICINE, INC. (KR) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157611-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE I ENZYME | DGAT1, DGAT2, SOAT1 | MCHR1 4494/4885MAP3K5 2069/4885NPC1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.